

2019 EMERGING THERAPIES FOR PBC, NASH ESLD AND HCC SEMINAR SERIES

Detroit, MI – June 1, 2019

Conference Location	DoubleTree Hotel - Dearborn 5801 Southfield Freeway Detroit, Michigan 48228-3885	Phone: (313) 336-3340 http://doubletree3.hilton.com/en/hotels/michigan/doubletree-by-hilton-hotel-detroit-dearborn-DTTDBDT/index.html
----------------------------	---	---

Parking at the Conference A reduced self-parking rate of \$2.00 has been arranged for all seminar participants. Please bring your ticket to the Seminar Registration Desk for validation.

Driving Directions

From the West (I-94): I-94 East to M-39 North (Southfield Freeway) to Ford Rd. (Exit 7) West. Once on Ford Rd. West, at 2nd light turn right.

From the West (I-96): I-96 East to M-39 South (Southfield Freeway) to Ford Rd. (Exit 7) West. Once on Ford Rd. West, at 1st light turn right.

From the East (I-94): I-94 West to M-39 North (Southfield Freeway) to Ford Rd. (Exit 7) West. Once on Ford Rd. West, at 2nd light turn right.

From the South (I-75): I-75 North to M-39 North (Southfield Freeway) to Ford Rd. (Exit 7) West. Once on Ford Rd. West, at 2nd light turn right.

From the South (US-24): US-24 (Telegraph Rd) to Ford Rd. East (Right Turn) and travel 3 mi., turn left just before Southfield Freeway entrance.

Seminar Agenda and Syllabus Information

Registration and breakfast begin at **7:30 a.m.** in the **Southfield Room**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

7:30 am	Registration, Continental Breakfast & View Exhibits
8:00 am	Opening Comments and Pre-Test
8:20 am	<p>End Stage Liver Disease: Treatment, Managing Complications and Transplant</p> <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease <p>Liver Transplantation</p> <ul style="list-style-type: none"> • Listing criteria, MELD scores, Exceptions and the transplant process <p>Case Study 1 – Cirrhosis and Encephalopathy</p>
9:25 am	<p>Hepatocellular Carcinoma (HCC)</p> <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	Break & View Exhibits
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options

	<ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival
11:25 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	<i>Luncheon and Educational Session “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C. Hosted by Alexion Pharmaceuticals</i>
12:45 pm	<i>Coffee and Dessert & View Exhibits</i>
1:00 pm	The Best Use of Non-Invasive Diagnostics for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes
1:30 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Treatment options for thrombocytopenia; including alternatives to platelet transfusion. • Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
2:15 pm	<i>Break & View Exhibits</i>
2:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH • Life style changes as a therapy • Drugs in clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:30 pm	Post-test and Wrap-Up

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1017. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.



ROBERT FONTANA, MD

Dr. Robert Fontana is an experienced hepatologist and translational investigator with research interests in drug induced liver injury, acute liver failure, and viral hepatitis in the transplant setting. Dr. Fontana completed his gastroenterology training at the University of Michigan and has been on the faculty since 1995. He is currently a Professor of Medicine and Medical Director of Liver Transplantation. He is a site principal investigator for the Drug Induced Liver Injury Network (DILIN) Registry study and also serves as Co-chair of the DILIN Steering committee. He has been an active member of the US Acute Liver Failure Study Group as a site investigator since 1998 and is now Co-PI of the overall network. Dr. Fontana is also the current Chair of the NIH Hepatitis B Research Network Publications Committee, Chair of the HBV Forum working group on Hepatotoxicity, and Chair of the CIOMS working group on DILI Biomarkers of the WHO


Your Seminar Faculty



DILIP MOONKA, MD

Dr. Dilip Moonka is the Medical Director of the Henry Ford Liver Transplant Program, is an expert in liver transplantation and hepatitis C. As previous director of Henry Ford's Viral Hepatitis Clinic, he developed unique and highly effective protocols for patients suffering from hepatitis B who are in need of liver transplantation. In addition, as director of clinical research in that division, he published studies on more effective and safer immunosuppressions.

Dr. Moonka also has extensive experience in clinical research on hepatitis C with both novel therapies and pegylated interferon. Dr. Moonka earned his medical degree from Stanford University in Palo Alto, California where he also completed a residency in internal medicine. He completed a fellowship in gastroenterology with advanced training in liver disease. He is board certified in internal medicine and gastroenterology



JEFFREY Mc MAHON, PA-C, MS

As a physician assistant in the Department of Gastroenterology/Hepatology, Jeff McMahon has enjoys his career in patient care at Henry Ford Hospital in Detroit, Michigan. Mr. McMahon holds a bachelor's degree from Western Michigan University in Kalamazoo and earned his Master in Science in Physician Assistant Studies from Wayne State University, Detroit, Michigan.

Mr. McMahon began his healthcare career as an Emergency Medical Technician while pursuing his Master's degree. He has both written and spoken on chronic liver disease and is an active member of the American Association for the Study of Liver Diseases, Society of Clinical Research Associates and the American Academy of Physician Assistants.
